Sareum Holdings PLC Result of AGM (7374I)
December 15 2020 - 6:59AM
UK Regulatory
TIDMSAR
RNS Number : 7374I
Sareum Holdings PLC
15 December 2020
SAREUM HOLDINGS PLC
("Sareum" or the "Company")
Results of AGM
Cambridge, UK, 15 December 2020 - Sareum Holdings plc (AIM:
SAR), the specialist drug development company delivering targeted
small molecule therapeutics to improve the treatment of cancer and
autoimmune diseases, held its Annual General Meeting ("AGM") today
and all resolutions were duly passed on a poll. Details of the
proxy voting are shown in the table below.
Ordinary resolutions Votes For % Votes Against % Votes Total % of Votes Withheld
ISC
Voted
1. Receive
the Annual
report and
accounts for
the Company 236,539,335 99.97 76,912 0.03 236,616,247 7.24 317,483
----------- ----- ------------- ---- ----------- ------ --------------
2. Approve
the Directors'
Remuneration
Report 225,264,050 98.71 2,946,682 1.29 228,210,732 6.98 8,722,998
----------- ----- ------------- ---- ----------- ------ --------------
3. Re-elect
Dr Stephen
Parker as a
director 225,888,456 95.36 10,980,647 4.64 236,869,103 7.25 64,627
----------- ----- ------------- ---- ----------- ------ --------------
4. Re-elect
Dr Tim Mitchell
as a director 236,331,048 99.77 538,055 0.23 236,869,103 7.25 64,627
----------- ----- ------------- ---- ----------- ------ --------------
5. Appoint
Shipleys LLP
as auditor 236,450,012 99.80 483,718 0.20 236,933,730 7.25 0
----------- ----- ------------- ---- ----------- ------ --------------
6. Directors'
authority to
allot new shares 229,589,440 97.03 7,026,807 2.97 236,616,247 7.24 317,483
----------- ----- ------------- ---- ----------- ------ --------------
Special Resolution
----------- ----- ------------- ---- ----------- ------ --------------
7. Disapplication
of pre-emption
rights 229,229,425 96.90 7,322,195 3.10 236,551,620 7.24 382,110
----------- ----- ------------- ---- ----------- ------ --------------
ISC - Issued Share Capital
The full text of each of the resolutions is set out in the
Notice of AGM, available in the Investors section of the Company's
website (www.sareum.com/investors)
For further information, please contact:
Sareum Holdings plc
Tim Mitchell, CEO 01223 497 700
Strand Hanson Limited (Nominated
Adviser)
James Dance / Richard Tulloch 020 7409 3494
Hybridan LLP (Nominated Broker)
Claire Noyce / John Beresford-Peirse 020 3764 2341
Citigate Dewe Rogerson (Financial
PR)
Mark Swallow/ David Dible 020 7638 9571
About Sareum
Sareum is a specialist drug development company delivering
targeted small molecule therapeutics to improve the treatment of
cancer and autoimmune diseases. The Company aims to generate value
through licensing its candidates to international pharmaceutical
and biotechnology companies at the preclinical or early clinical
trials stage.
Sareum is advancing internal programmes focused on distinct dual
tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through
preclinical development as therapies for autoimmune diseases,
including the 'cytokine storm' immune system overreaction to
Covid-19 and other viral infections, (SDC-1801) and cancer
immunotherapy (SDC-1802).
The Company's preclinical FLT3+Aurora inhibitor programme
targeting haematological cancers is licensed to a China-based
specialty pharma company.
Sareum also has an economic interest in SRA737, a clinical-stage
oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets
cancer cell replication and DNA damage repair mechanisms.
Preliminary Phase 2 and comprehensive preclinical data suggest
SRA737 may have broad application in combination with other
oncology and immune-oncology drugs in genetically defined
patients.
SRA737 was discovered and initially developed by scientists at
The Institute of Cancer Research in collaboration with Sareum, and
with funding from Sareum and Cancer Research UK. SRA737 was
licensed by CRT Pioneer Fund (CPF) to Sierra Oncology Inc. Sierra
continues to explore options that would enable the development of
SRA737 to advance.
Sareum Holdings plc is listed on the AIM market of the London
Stock Exchange, trading under the ticker SAR. For further
information, please visit the Company's website at
www.sareum.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
RAGKKPBPBBDDOBD
(END) Dow Jones Newswires
December 15, 2020 07:59 ET (12:59 GMT)
Sareum (LSE:SAR)
Historical Stock Chart
From Apr 2024 to May 2024
Sareum (LSE:SAR)
Historical Stock Chart
From May 2023 to May 2024